Sign up to save your podcasts
Or
Share Extending Horizons With Immune Checkpoint Inhibitors in Small Cell Lung Cancer: 2022 Perspectives
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Extending Horizons With Immune Checkpoint Inhibitors in Small Cell Lung Cancer: 2022 Perspectives
Patients with extensive-stage small cell lung cancer (ES-SCLC) have a 10-month survival of 10 months following standard frontline chemotherapy. Join the experts in discussing immune checkpoint inhibitors (ICIs) in patients with SCLC.
Credit available for this activity expires: 6/15/2023
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975532?src=mkm_podcast_addon_975532
View all episodes
By Medscape Podcasts
4
77 ratings
Patients with extensive-stage small cell lung cancer (ES-SCLC) have a 10-month survival of 10 months following standard frontline chemotherapy. Join the experts in discussing immune checkpoint inhibitors (ICIs) in patients with SCLC.
Credit available for this activity expires: 6/15/2023
Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/975532?src=mkm_podcast_addon_975532
More shows like Keeping Current
View all
JAMA Editors' Summary
138 Listeners
NEJM This Week
322 Listeners
JAMA Clinical Reviews
498 Listeners
Diabetes Core Update
102 Listeners
This Week in Cardiology
881 Listeners
The Bob Harrington Show
13 Listeners
One-on-One with Eric Topol
17 Listeners
Mayo Clinic Talks
288 Listeners
The Curbsiders Internal Medicine Podcast
3,339 Listeners
Core IM | Internal Medicine Podcast
1,154 Listeners
Annals On Call Podcast
192 Listeners
JAMA Medical News
88 Listeners
The Clinical Problem Solvers
513 Listeners
Harrison's PodClass: Internal Medicine Cases and Board Prep
369 Listeners
Medicine and the Machine
61 Listeners
Keeping Current CME
26 Listeners
Cardionerds: A Cardiology Podcast
431 Listeners
The Curious Clinicians
372 Listeners